These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 23518819)
41. Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure. Yurista SR; Matsuura TR; Silljé HHW; Nijholt KT; McDaid KS; Shewale SV; Leone TC; Newman JC; Verdin E; van Veldhuisen DJ; de Boer RA; Kelly DP; Westenbrink BD Circ Heart Fail; 2021 Jan; 14(1):e007684. PubMed ID: 33356362 [TBL] [Abstract][Full Text] [Related]
42. Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction. Alex L; Russo I; Holoborodko V; Frangogiannis NG Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H934-H949. PubMed ID: 30004258 [TBL] [Abstract][Full Text] [Related]
43. The Athena trials: Autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction. Henry TD; Pepine CJ; Lambert CR; Traverse JH; Schatz R; Costa M; Povsic TJ; David Anderson R; Willerson JT; Kesten S; Perin EC Catheter Cardiovasc Interv; 2017 Feb; 89(2):169-177. PubMed ID: 27148802 [TBL] [Abstract][Full Text] [Related]
44. Full Expression of Cardiomyopathy Is Partly Dependent on B-Cells: A Pathway That Involves Cytokine Activation, Immunoglobulin Deposition, and Activation of Apoptosis. Cordero-Reyes AM; Youker KA; Trevino AR; Celis R; Hamilton DJ; Flores-Arredondo JH; Orrego CM; Bhimaraj A; Estep JD; Torre-Amione G J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26769625 [TBL] [Abstract][Full Text] [Related]
45. Comparison of Mesenchymal Stem Cell Efficacy in Ischemic Versus Nonischemic Dilated Cardiomyopathy. Tompkins BA; Rieger AC; Florea V; Banerjee MN; Natsumeda M; Nigh ED; Landin AM; Rodriguez GM; Hatzistergos KE; Schulman IH; Hare JM J Am Heart Assoc; 2018 Jul; 7(14):. PubMed ID: 30005555 [TBL] [Abstract][Full Text] [Related]
46. Cardiac remodelling and myocardial recovery: lost in translation? Mann DL; Bogaev R; Buckberg GD Eur J Heart Fail; 2010 Aug; 12(8):789-96. PubMed ID: 20675667 [TBL] [Abstract][Full Text] [Related]
47. A look between the cardiomyocytes: the extracellular matrix in heart failure. Miner EC; Miller WL Mayo Clin Proc; 2006 Jan; 81(1):71-6. PubMed ID: 16438481 [TBL] [Abstract][Full Text] [Related]
48. Stem cell therapy: pieces of the puzzle. Schoenhard JA; Hatzopoulos AK J Cardiovasc Transl Res; 2010 Feb; 3(1):49-60. PubMed ID: 20119487 [TBL] [Abstract][Full Text] [Related]
49. Hybrid transcatheter left ventricular reconstruction for the treatment of ischaemic cardiomyopathy. Zivelonghi C; Klein P; Swaans MJ; Agostoni P EuroIntervention; 2018 Mar; 13(16):1899-1901. PubMed ID: 28966158 [No Abstract] [Full Text] [Related]
50. Myocardial insulin-like growth factor-I gene expression during recovery from heart failure after combined left ventricular assist device and clenbuterol therapy. Barton PJ; Felkin LE; Birks EJ; Cullen ME; Banner NR; Grindle S; Hall JL; Miller LW; Yacoub MH Circulation; 2005 Aug; 112(9 Suppl):I46-50. PubMed ID: 16159864 [TBL] [Abstract][Full Text] [Related]
51. Surgical therapy of end-stage heart failure: understanding cell-mediated mechanisms interacting with myocardial damage. Ghodsizad A; Loebe M; Piechaczek C; Bordel V; Ungerer MN; Gregoric I; Bruckner B; Noon GP; Karck M; Ruhparwar A Int J Artif Organs; 2011 Jul; 34(7):529-45. PubMed ID: 21786252 [TBL] [Abstract][Full Text] [Related]
52. Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. Yarbrough WM; Mukherjee R; Ikonomidis JS; Zile MR; Spinale FG J Thorac Cardiovasc Surg; 2012 Mar; 143(3):656-64. PubMed ID: 21762938 [TBL] [Abstract][Full Text] [Related]
53. Metabolic manipulation in chronic heart failure: study protocol for a randomised controlled trial. Beadle RM; Williams LK; Abozguia K; Patel K; Leon FL; Yousef Z; Wagenmakers A; Frenneaux MP Trials; 2011 Jun; 12():140. PubMed ID: 21645332 [TBL] [Abstract][Full Text] [Related]
57. Relationship Between Focal and Diffuse Fibrosis Assessed by CMR and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. Kanagala P; Cheng ASH; Singh A; Khan JN; Gulsin GS; Patel P; Gupta P; Arnold JR; Squire IB; Ng LL; McCann GP JACC Cardiovasc Imaging; 2019 Nov; 12(11 Pt 2):2291-2301. PubMed ID: 30772227 [TBL] [Abstract][Full Text] [Related]
58. A new heart: somatic stem cells and myocardial regeneration. Mullenix PS; Huddleston SJ; Stojadinovic A; Trachiotis GD; Alexander EP J Surg Oncol; 2012 Apr; 105(5):475-80. PubMed ID: 22441899 [TBL] [Abstract][Full Text] [Related]
59. CT for evaluation of myocardial cell therapy in heart failure: a comparison with CMR imaging. Schuleri KH; Centola M; Choi SH; Evers KS; Dawoud F; George RT; Lima JA; Lardo AC JACC Cardiovasc Imaging; 2011 Dec; 4(12):1284-93. PubMed ID: 22172785 [TBL] [Abstract][Full Text] [Related]
60. Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. Teerlink JR; Metra M; Filippatos GS; Davison BA; Bartunek J; Terzic A; Gersh BJ; Povsic TJ; Henry TD; Alexandre B; Homsy C; Edwards C; Seron A; Wijns W; Cotter G; Eur J Heart Fail; 2017 Nov; 19(11):1520-1529. PubMed ID: 28560782 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]